Association between tamoxifen treatment and diabetes: A population‐based study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is increasing evidence linking breast cancer and diabetes; however, few studies have explored the association between cancer treatments and risk of diabetes. Tamoxifen may increase diabetes incidence through its estrogen‐inhibiting effects. This study assessed whether tamoxifen treatment in older breast cancer survivors is associated with an increased risk of diabetes. METHODS: This nested case‐control study used population‐based health databases in Ontario, Canada to identify women older than 65 years with early stage breast cancer between April 1, 1996 and March 31, 2006. Cases were defined as cohort members diagnosed with diabetes during follow‐up (March 31, 2008), and each case was age‐matched with up to 5 controls who did not develop diabetes. After adjusting for other risk factors, the authors compared the likelihood of diabetes between current tamoxifen users and tamoxifen nonusers, based on prescriptions at diabetes diagnosis. They also compared diabetes risk in current aromatase inhibitor users versus nonusers. RESULTS: Of 14,360 breast cancer survivors identified, mean age 74.9 years, 1445 (10%) developed diabetes over a mean follow‐up of 5.2 years. Current tamoxifen therapy was associated with a significantly higher risk of diabetes compared with no tamoxifen therapy (adjusted odds ratio, 1.24; 95% confidence interval, 1.08‐1.42; P = .002). There was no association between aromatase inhibitor therapy and diabetes. CONCLUSIONS: Current tamoxifen therapy is associated with an increased incidence of diabetes in older breast cancer survivors. These findings suggest that tamoxifen treatment may exacerbate an underlying risk of diabetes in susceptible women; further studies are needed to better explore this association. Cancer 2011. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emergence of the Metabolic Syndrome with Menopause
Carr, M. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030242 · Cited by 1,449 · cited 1×
“The decline in estrogen after menopause is also associated with weight gain, insulin resistance, and the metabolic syndrome.(26) Moreover, postmenopausal estrogen replacement has been shown to reduce the incidence of diabetes in clinical trials.”
BackgroundBarone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881
Yang, X. R., Chang-Claude, J., Goode, E. L., Couch, F. J., Nevanlinna, H., Milne, R. L., Gaudet, M., Schmidt, M. K., Broeks, A., Cox, A., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq526 · Cited by 691
Self-citationfor the Women’s Health Initiative Investigators, Margolis, K. L., Bonds, D. E., Rodabough, R. J., Tinker, L., Phillips, L. S., Allen, C., Bassford, T., Burke, G., Torrens, J., et al. (2004) · Diabetologia · doi:10.1007/s00125-004-1448-x · Cited by 599 · cited 2×
“Estrogen replacement was also found to lower the risk of diabetes in clinical trials.(18,19) Furthermore, tamoxifen has been shown to directly suppress insulin secretion in mice.”
BackgroundBryzgalova, G., Gao, H., Ahren, B., Zierath, J. R., Galuska, D., Steiler, T. L., Dahlman-Wright, K., Nilsson, S., Gustafsson, J.-Å., Efendic, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0105-3 · Cited by 384
The impact of diabetes on survival following breast cancer
Lipscombe, L. L., Goodwin, P. J., Zinman, B., McLaughlin, J. R., & Hux, J. E. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9654-0 · Cited by 176
Cited by
The role of estrogens in control of energy balance and glucose homeostasis
Mauvais-Jarvis, F., Clegg, D. J., & Hevener, A. L. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1055 · Cited by 1,329
Review: Diabetes, Obesity, and Cancer—Pathophysiology and Clinical Implications
Lega, I. C., & Lipscombe, L. L. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz014 · Cited by 364
Self-citationDiabetes and cancer: two diseases with obesity as a common risk factor
Garg, S. K., Maurer, H., Reed, K., & Selagamsetty, R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12124 · Cited by 275
Kim, J. H., Cho, H. T., & Kim, Y. J. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0262 · Cited by 111
A guideline for the outpatient management of glycaemic control in people with cancer
Joharatnam‐Hogan, N., Chambers, P., Dhatariya, K., Board, R., & the Joint British Diabetes Society for Inpatient Care (JBDS), U. C. B. (. (2022) · Diabetic Medicine · doi:10.1111/dme.14636 · Cited by 50
Metadata
- Authors
- Lipscombe, L. L., Fischer, H. D., Yun, L., Gruneir, A., Austin, P., Paszat, L., Anderson, G. M., & Rochon, P. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-09-20
- Volume
- 118
- Issue
- 10
- Pages
- 2615-2622
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1480532714
- Cited by
- 79
- References
- 6
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.